# InMed Pharmaceuticals (NASDAQ: INM) Subsidiary BayMedica Releases Market Report for 2023 on “Minor Cannabinoids”

* The report explores the growth, competition, and consumer trends, for lesser known cannabinoids
* The report highlights a 5.4% revenue increase in the edible market for 2023, with total sales reaching $2.097 billion
* As consumer preferences shift towards edibles for their therapeutic effects and consistent experiences, the industry product landscape is set to evolve

 With the increasing acceptance of cannabis use in society, the popularity of edibles—products containing cannabinoids that can be consumed as food or drink—has surged. While many consumers are familiar with edibles containing THC (tetrahydrocannabinol), known for its euphoric effects, or CBD (cannabidiol), recognized for its therapeutic benefits, there is a growing interest in edibles infused with non-intoxicating minor cannabinoids. These lesser-known cannabinoids offer unique properties and potential health benefits, driving significant market growth.

 BayMedica, a subsidiary of InMed Pharmaceuticals (NASDAQ: INM), specializes in rare cannabinoids, and has published a report on the expansion of the minor cannabinoid market in 2023. Link to a full copy of…

 Read More>>

 NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://cnw.fm/INM

 About CannabisNewsWire

 CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

 To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

 For more information, please visit https://www.CannabisNewsWire.com

 Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

 CannabisNewsWireDenver, COwww.CannabisNewsWire.com303.498.7722 OfficeEditor@CannabisNewsWire.com

 CannabisNewsWire is powered by IBN 

---

[Original/Source Press Release](https://rss.investorbrandnetwork.com/ibn-prem/inmed-pharmaceuticals-nasdaq-inm-subsidiary-baymedica-releases-market-report-for-2023-on-minor-cannabinoids/)
                    

[Newsramp.com TLDR](https://newsramp.com/curated-news/baymedica-report-reveals-major-growth-in-lesser-known-cannabinoids-market/f5ae5ddb890484495546d6e00b05d042) 

 



[Reddit Post](https://www.reddit.com/r/CannabisNewsInfo/comments/1f2fgh7/baymedica_report_reveals_major_growth_in_lesser/) 



![Blockchain Registration](https://cdn.newsramp.app/ibn/qrcode/248/27/beancgbm.webp)